期刊文献+

巨大动脉导管未闭合并肺动脉高压患者介入封堵的可行性和有效性研究 被引量:7

Safety and efficiency of occluding giant patent ductus arteriosus with severe pulmonary hypertension using occluder
下载PDF
导出
摘要 目的应用封堵器治疗巨大动脉导管未闭(PDA)伴重度肺动脉高压(SPH)患者,并评价其临床疗效。方法回顾性分析26例巨大PDA合并SPH患者,应用封堵器封堵PDA,观察封堵前及封堵后肺动脉压力改变,术后随访6个月。结果 23例封堵成功,PDA最窄处直径8-18.0 mm,平均(12.2±4.6)mm。术前肺动脉收缩压为(98.3±23.4)mmHg,平均压为(69.1±15.0)mmHg,封堵后30分钟测肺动脉收缩压为(44.6±10.6)mmHg,平均压为(28.9±7.3)mmHg,较封堵前显著降低(P〈0.01),3例PDA伴SPH者术中试封堵证实为阻力性肺动脉高压而放弃干预。封堵后30分钟降主动脉造影示22例封堵完全,无残余分流,1例存在中量残余分流。术后24小时超声心动图示1例仍存在微量残余分流,1个月后所有患者均未见残余分流,术后未见溶血、封堵器脱落、移位并发症。结论应用封堵器治疗巨大PDA伴SPH的患者是一种可行的、有效的介入方法。 Objective To evaluate the efficiency of transcatheter closure of giant patent ductus arteriosus(PDA) with severe pulmonary hypertension(SPH) using the occluder.Methods 26 patients of giant PDA with SPH were reviewed,they were treated by transcatheter closure with domastic made occluder.Follow-up evaluations were performed with echocardiogram and Doppler at 24 h and 1,3 and 6 months after implantation.Results The devices were successfully placed in 23 patients.The systolic pulmonary pressure decreased from(98.3±23.4) mmHg to(44.6±10.6) mmHg,and the mean pulmonary pressure decreased from(69.1±15.0) mmHg to(28.9±7.3) mmHg(P〈0.05).The occluder was removed in 3 patients,because of resistant pulmonary hypertension after the experimental closure.Angiographic complete closure was seen in 22 patients,while medium leak was present in 1 patient.Complete echocardiographic closure was demonstrated in all patients after 1 month.Neither displacement of the device,nor hemolysis or left pulmonary stenosis occurred during follow-up.Conclusion Transcatheter closure of PDA with SPH by using domastic made occluder is safe and effective.
出处 《临床荟萃》 CAS 2011年第17期1473-1475,1479,共4页 Clinical Focus
关键词 动脉导管未闭 高血压 肺性 超声检查 介入性 ductus arteriosus patent hypertension pulmonary ultrasonography interventional
  • 相关文献

参考文献11

  • 1Krichenko A, Benson LN, Burrows P, et al. Angiographic classification of the isolated persistently patent ductus arteriosus and implicat ion for percutaneous catheter occlusion [J]. Am J Cardiol, 1989,63 (1) : 877-880. 被引量:1
  • 2无.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35(11):979-987. 被引量:271
  • 3Simonneau G,Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension [J]. J Am Coll Cardiol, 2004, 43 (Suppl) :S5-12. 被引量:1
  • 4Galie N,Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension:the Task Force on Diagnosis and Treatment of Pulmonary Artrial Hypertension of the European Society of Cardiology[J]. Eur Heart J, 2004,25 (1) :2243-2278. 被引量:1
  • 5Gaine S. Pulnomary hypertension [J]. Chest, 2005, 128 (8 Suppl) :642S-646S. 被引量:1
  • 6Heath D, Edwards J. The pathology of hypertensive pulmonary vascular diease:a description of six grades of structural changes in the pulmonary arteries with special refer encetocongenital cardiac septal defcts[J]. Circulation, 1958,18 ( 2 ) : 533-547. 被引量:1
  • 7Wagenvoort CA. Grading of pulmonary vascular lezions-a reappraisal[J]. Histopathology, 1981,5(2) :595-598. 被引量:1
  • 8Masura J, Walsh KP, Thanopoulous B, et al. Catheter closure of moderate to large-sized patent ductus arteriosus using the new Amplatzer Duct Occluder: immediate and short-term rcsults[J].J Am Coll Cardiol,1998,31(4) :878-879. 被引量:1
  • 9Faella H J, Hijazi ZM. Closure of the patent ductus arteriosus with the amplatzer PDA device: immediate results of the international clinical trial [J].Catheter Cardiovasc Interv, 2000,51(2) :50-52. 被引量:1
  • 10Bilkis AA, Alwi M, Hasri S, et al. The Amplatzer duct occluder, experience in 209 patients [J].J Am Coll Cardiol, 2001,37(5) :258-260. 被引量:1

二级参考文献31

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 3Proceeding of 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol, 2004,43(2 Suppl S) : 1S-90S. 被引量:1
  • 4Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126( Suppl 1 ) : 1 S-92S. 被引量:1
  • 5Galie N, Torbicki A, Barst A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004,25 ( 24 ) : 2243-2278. 被引量:1
  • 6Barst RJ, McGoon M, Torbicki A,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2004,43( 12 Suppl S) :40S-47S. 被引量:1
  • 7Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004,43 (12) :5S-12S. 被引量:1
  • 8Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol, 2004,43(12 Suppl S) :25S-32S. 被引量:1
  • 9McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension : ACCP evidence-based clinical practice guidelines. Chest, 2004,126 (1 Suppl): 14S-34S. 被引量:1
  • 10Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med, 2006,173 (9) :1023-1030. 被引量:1

共引文献270

同被引文献52

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部